Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage, node-positive breast cancer: sequencing, timing, and outcome.
Abram Recht(Beth Israel Deaconess Medical Center), James L. Connolly(Beth Israel Deaconess Medical Center), Steven E. Come, Rebecca Gelman(Dana-Farber Cancer Institute), Barbara Silver(Brigham and Women's Hospital), Michael A. Goldstein(Babson College), S Tishler, Frank A. Vicini(Radiation Oncology Institute), Stacey M. Gore, Anthony Abner(Dana-Farber Brigham Cancer Center)
Cited by 166
Related Papers
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Prognostic Factors in Breast Cancer
|Archives of Pathology & Laboratory Medicine|2000|1.1k
Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|988
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2010|983